Company Encyclopedia
View More
name
ZHBIO
300653.SZ
Yantai Zhenghai Biotechnology Co., Ltd. engages in the research and development, production, and sales of bioregenerative medical materials in China. The company offers oral repair membranes, absorbable dura mater patches, active biological bones, skin repair membranes, bone repair materials, surgical packing sponges, phosphoric acid etchant, dental pit and fissure sealant, light-curing composite resin, non-absorbable surgical sutures, and self-etching adhesives. It products are used in various fields, such as dentistry, head and neck surgery, neurosurgery, and otolaryngology.
1.557 T
300653.SZMarket value -Rank by Market Cap -/-

Financial Score

23/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking53/81
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE8.70%B
    • Profit Margin22.15%A
    • Gross Margin87.95%A
  • Growth ScoreD
    • Revenue YoY-9.30%D
    • Net Profit YoY-54.09%D
    • Total Assets YoY-1.28%D
    • Net Assets YoY-2.28%D
  • Cash ScoreD
    • Cash Flow Margin451.51%C
    • OCF YoY-9.30%D
  • Operating ScoreC
    • Turnover0.36C
  • Debt ScoreA
    • Gearing Ratio9.37%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    ZHBIO released its performance for the first three quarters, with a net profit attributable to the parent company of 67.4022 million yuan, a decrease of 46.10%

    ZHBIO released its third-quarter report for 2025, with operating revenue of 276 million yuan in the first three quarters, a year-on-year decrease of 5.36%. The net profit attributable to the parent company was 67.4022 million yuan, a year-on-year decline of 46.10%; the net profit excluding non-recurring gains and losses was 59.1816 million yuan, a year-on-year decrease of 45.34%. The basic earnings per share were 0.37 yuan

    Zhitong·
    SZ
    300653
    -0.39%
    Zhitong·
    SZ
    300653
    -0.39%

    ZHBIO: Oral absorbable biological membrane completes the enrollment of the first subject

    ZHBIO announced that the company's research and development project "Oral Resorbable Biomembrane" has officially entered clinical trials. This clinical trial is a multicenter, randomized controlled, single-blind, non-inferiority trial aimed at evaluating the efficacy and safety of the oral resorbable biomembrane for guiding bone regeneration. Currently, the project has successfully completed the random enrollment of the first subject. The oral resorbable biomembrane, as a decellularized dermal matrix material, can provide a good scaffold for cell ingrowth and migration, thereby guiding the growth and deposition of bone tissue to achieve reparative regeneration in bone defect areas

    Zhitong·
    SZ
    300653
    -0.39%
    Zhitong·
    SZ
    300653
    -0.39%

    ZHBIO: Currently carrying out relevant planning work for product overseas expansion

    ZHBIO is planning to launch its products overseas. In the first half of the year, the company's new oral repair membrane received certification, and calcium silicate bioceramic bone repair materials entered the registration stage. This will enrich the company's layout in the oral field and enhance its product portfolio capabilities. Other products, such as intrauterine repair membranes and breast patches, are also being advanced in an orderly manner, and are expected to bring incremental revenue to the company in the next 2-3 years

    Zhitong·
    SZ
    300653
    -0.39%
    Zhitong·
    SZ
    300653
    -0.39%

    ZHBIO released its performance for the first half of the year, with a net profit attributable to the parent company of 46.4857 million yuan, a decrease of 45.97%

    According to the Zhitong Finance APP, ZHBIO released its semi-annual report for 2025, showing that the company's operating income was 188 million yuan, a year-on-year decrease of 5.14%. The net profit attributable to shareholders of the listed company was 46.4857 million yuan, a year-on-year decrease of 45.97%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 40.2807 million yuan, a year-on-year decrease of 46.77%. The basic earnings per share were 0.26 yuan

    Zhitong·
    SZ
    300653
    -0.39%
    Zhitong·
    SZ
    300653
    -0.39%

    ZHBIO: Calcium silicate bioceramic bone repair materials are expected to be approved within the year

    On May 13th, ZHBIO stated during an institutional research that in terms of R&D, the company continues to refine its product industrialization capabilities, striving for more new product approvals. In January of this year, the company's second-generation oral repair membrane was approved, and the calcium silicate bioceramic bone repair material is expected to be approved within the year, which will help enrich the company's product matrix in the oral field. Other major products in the clinical stage include intrauterine repair membranes and breast patches. The successive launch of these products will expand the company's downstream application departments to obstetrics and gynecology, breast surgery, and more

    Zhitong·
    SZ
    300653
    -0.39%
    Zhitong·
    SZ
    300653
    -0.39%
    © 2025 Longbridge｜Disclaimer